184 related articles for article (PubMed ID: 32519033)
1. YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
Zhu Y; Liu Z; Qu Y; Zeng J; Yang M; Li X; Wang Z; Su J; Wang X; Yu L; Wang Y
Cancer Chemother Pharmacol; 2020 Jul; 86(1):33-43. PubMed ID: 32519033
[TBL] [Abstract][Full Text] [Related]
2. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
Lei Q; Xiong L; Xia Y; Feng Z; Gao T; Wei W; Song X; Ye T; Wang N; Peng C; Li Z; Liu Z; Yu L
Cell Death Dis; 2018 Oct; 9(11):1066. PubMed ID: 30337519
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma.
Zhao Y; Yang J; Liu J; Cai Y; Han Y; Hu S; Ren S; Zhou X; Wang X
Cell Death Dis; 2021 Jun; 12(7):640. PubMed ID: 34162828
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.
Kawakami M; Mustachio LM; Zheng L; Chen Y; Rodriguez-Canales J; Mino B; Kurie JM; Roszik J; Villalobos PA; Thu KL; Silvester J; Cescon DW; Wistuba II; Mak TW; Liu X; Dmitrovsky E
Proc Natl Acad Sci U S A; 2018 Feb; 115(8):1913-1918. PubMed ID: 29434041
[TBL] [Abstract][Full Text] [Related]
5. Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts.
Lohse I; Mason J; Cao PM; Pintilie M; Bray M; Hedley DW
Oncotarget; 2017 Jan; 8(2):3064-3071. PubMed ID: 27902970
[TBL] [Abstract][Full Text] [Related]
6. PLK4: a link between centriole biogenesis and cancer.
Maniswami RR; Prashanth S; Karanth AV; Koushik S; Govindaraj H; Mullangi R; Rajagopal S; Jegatheesan SK
Expert Opin Ther Targets; 2018 Jan; 22(1):59-73. PubMed ID: 29171762
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.
Mason JM; Lin DC; Wei X; Che Y; Yao Y; Kiarash R; Cescon DW; Fletcher GC; Awrey DE; Bray MR; Pan G; Mak TW
Cancer Cell; 2014 Aug; 26(2):163-76. PubMed ID: 25043604
[TBL] [Abstract][Full Text] [Related]
8. Autophosphorylation of polo-like kinase 4 and its role in centriole duplication.
Sillibourne JE; Tack F; Vloemans N; Boeckx A; Thambirajah S; Bonnet P; Ramaekers FC; Bornens M; Grand-Perret T
Mol Biol Cell; 2010 Feb; 21(4):547-61. PubMed ID: 20032307
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of targeting polo-like kinase 4.
Lei Q; Yu Q; Yang N; Xiao Z; Song C; Zhang R; Yang S; Liu Z; Deng H
Eur J Med Chem; 2024 Feb; 265():116115. PubMed ID: 38199166
[TBL] [Abstract][Full Text] [Related]
10. PLK4: a promising target for cancer therapy.
Zhao Y; Wang X
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2413-2422. PubMed ID: 31492983
[TBL] [Abstract][Full Text] [Related]
11. Non-mitotic functions of polo-like kinases in cancer cells.
Raab CA; Raab M; Becker S; Strebhardt K
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
[TBL] [Abstract][Full Text] [Related]
12. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Valsasina B; Beria I; Alli C; Alzani R; Avanzi N; Ballinari D; Cappella P; Caruso M; Casolaro A; Ciavolella A; Cucchi U; De Ponti A; Felder E; Fiorentini F; Galvani A; Gianellini LM; Giorgini ML; Isacchi A; Lansen J; Pesenti E; Rizzi S; Rocchetti M; Sola F; Moll J
Mol Cancer Ther; 2012 Apr; 11(4):1006-16. PubMed ID: 22319201
[TBL] [Abstract][Full Text] [Related]
13. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
[TBL] [Abstract][Full Text] [Related]
14. GCP6 is a substrate of Plk4 and required for centriole duplication.
Bahtz R; Seidler J; Arnold M; Haselmann-Weiss U; Antony C; Lehmann WD; Hoffmann I
J Cell Sci; 2012 Jan; 125(Pt 2):486-96. PubMed ID: 22302995
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 4 controls centriole duplication but does not directly regulate cytokinesis.
Holland AJ; Fachinetti D; Da Cruz S; Zhu Q; Vitre B; Lince-Faria M; Chen D; Parish N; Verma IM; Bettencourt-Dias M; Cleveland DW
Mol Biol Cell; 2012 May; 23(10):1838-45. PubMed ID: 22456511
[TBL] [Abstract][Full Text] [Related]
16. CDK11(p58) is required for centriole duplication and Plk4 recruitment to mitotic centrosomes.
Franck N; Montembault E; Romé P; Pascal A; Cremet JY; Giet R
PLoS One; 2011 Jan; 6(1):e14600. PubMed ID: 21297952
[TBL] [Abstract][Full Text] [Related]
17. The Protein Phosphatase 2A regulatory subunit Twins stabilizes Plk4 to induce centriole amplification.
Brownlee CW; Klebba JE; Buster DW; Rogers GC
J Cell Biol; 2011 Oct; 195(2):231-43. PubMed ID: 21987638
[TBL] [Abstract][Full Text] [Related]
18. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.
Laufer R; Forrest B; Li SW; Liu Y; Sampson P; Edwards L; Lang Y; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Beletskaya I; Mason JM; Luo X; Wei X; Yao Y; Feher M; Ban F; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
J Med Chem; 2013 Aug; 56(15):6069-87. PubMed ID: 23829549
[TBL] [Abstract][Full Text] [Related]
19. Role for polo-like kinase 4 in mediation of cytokinesis.
Press MF; Xie B; Davenport S; Zhou Y; Guzman R; Nolan GP; O'Brien N; Palazzolo M; Mak TW; Brugge JS; Slamon DJ
Proc Natl Acad Sci U S A; 2019 Jun; 116(23):11309-11318. PubMed ID: 31097597
[TBL] [Abstract][Full Text] [Related]
20. Cep152 interacts with Plk4 and is required for centriole duplication.
Hatch EM; Kulukian A; Holland AJ; Cleveland DW; Stearns T
J Cell Biol; 2010 Nov; 191(4):721-9. PubMed ID: 21059850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
